胰高血糖素样肽-1（GLP-1）激动剂与心脏代谢保护：历史发展与未来挑战
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges.
作者信息
Westermeier Francisco, Fisman Enrique Z
机构信息
Institute of Biomedical Science, Department of Health Studies, FH Joanneum University of Applied Sciences, Graz, Austria.
Centro de Biología y Química Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile.
出版信息
Cardiovasc Diabetol. 2025 Jan 29;24(1):44. doi: 10.1186/s12933-025-02608-9.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of GLP-1 to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential.
摘要
胰高血糖素样肽-1受体激动剂（GLP-1RAs）彻底改变了心脏代谢疾病的治疗方式，其治疗应用范围已远远超出了2型糖尿病（T2D）和肥胖症的血糖控制。这篇社论总结了从GLP-1的发现到近期临床试验的关键里程碑，这些试验突出了GLP-1RAs在解决相互关联的心脏代谢疾病谱方面的多效性作用，重点关注其对心血管、肾脏和肝脏的益处。此外，随着GLP-1RAs继续重塑心脏代谢疾病的管理和全球公共卫生状况，我们讨论了未来的挑战，以更好地阐明其心脏代谢保护机制并最大限度地发挥其治疗潜力。
相似文献
1
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges.胰高血糖素样肽-1（GLP-1）激动剂与心脏代谢保护：历史发展与未来挑战
Cardiovasc Diabetol. 2025 Jan 29;24(1):44. doi: 10.1186/s12933-025-02608-9.
2
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.GLP-1RAs 在 2 型糖尿病中的作用机制：心血管效应的基础及心血管结局数据概述。
Cardiovasc Diabetol. 2018 Dec 13;17(1):157. doi: 10.1186/s12933-018-0800-2.
3
Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.胰高血糖素样肽-1 受体激动剂治疗慢性肾脏病伴 2 型糖尿病患者的疗效及其对肾脏的影响评价。
J Diabetes. 2019 Dec;11(12):938-948. doi: 10.1111/1753-0407.12969. Epub 2019 Aug 14.
4
Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.在2型糖尿病中，将新一代胰高血糖素样肽-1受体激动剂（GLP-1RA）添加到钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）中的真实世界有效性。
Cardiovasc Diabetol. 2025 Apr 24;24(1):177. doi: 10.1186/s12933-025-02737-1.
5
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
6
Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.2 型糖尿病的患者重要结局：钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的范例。
Diab Vasc Dis Res. 2024 Jul-Aug;21(4):14791641241269743. doi: 10.1177/14791641241269743.
7
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes.胰高血糖素样肽 1 受体激动剂的心血管作用：从人体的机制研究到临床结局。
Cardiovasc Res. 2020 Apr 1;116(5):916-930. doi: 10.1093/cvr/cvz323.
8
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.双重葡萄糖依赖性胰岛素促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体激动剂替西帕肽：一种新的代谢治疗前景。
Cardiovasc Diabetol. 2021 Nov 24;20(1):225. doi: 10.1186/s12933-021-01412-5.
9
The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂对非酒精性脂肪性肝病糖尿病患者血糖控制和人体测量特征的影响：系统评价和随机对照试验的荟萃分析。
Eur J Pharmacol. 2021 Feb 15;893:173823. doi: 10.1016/j.ejphar.2020.173823. Epub 2020 Dec 19.
10
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.GLP-1 受体激动剂和 SGLT2 抑制剂及非奈利酮联合治疗的心血管和肾脏效应的更新证据：叙述性评价和观点。
Cardiovasc Diabetol. 2024 Nov 15;23(1):410. doi: 10.1186/s12933-024-02500-y.
引用本文的文献
1
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025).GLP-1疗法的新兴前沿：全面的证据基础（2025年）
Pharmaceutics. 2025 Aug 9;17(8):1036. doi: 10.3390/pharmaceutics17081036.
2
Repurposing GLP-1 Receptor Agonists: A Perspective on Epigenetic Strategies to Combat Fibrosis and Hepatocellular Carcinoma in the Aged Liver.重新利用胰高血糖素样肽-1受体激动剂：对抗老年肝脏纤维化和肝细胞癌的表观遗传策略展望。
Cancers (Basel). 2025 Aug 8;17(16):2600. doi: 10.3390/cancers17162600.
3
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.MAFLD：代谢功能障碍与心血管风险之间联系的全面综述
Hepat Med. 2025 Aug 19;17:75-90. doi: 10.2147/HMER.S506402. eCollection 2025.
4
Economic evaluation of liraglutide vs dulaglutide or oral semaglutide in patients with type 2 diabetes mellitus: a systematic review.利拉鲁肽与度拉鲁肽或口服司美格鲁肽治疗2型糖尿病患者的经济学评价：一项系统评价
Diabetol Metab Syndr. 2025 Aug 27;17(1):358. doi: 10.1186/s13098-025-01927-x.
5
Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation.治疗性肽：发现、合成及临床转化的最新进展
Int J Mol Sci. 2025 May 27;26(11):5131. doi: 10.3390/ijms26115131.
6
Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications.胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂在神经性疼痛中的治疗作用：作用机制及临床意义
Biomolecules. 2025 Apr 26;15(5):622. doi: 10.3390/biom15050622.
7
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂（GLP-1RA）的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
8
Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges.更正：胰高血糖素样肽-1受体激动剂（GLP-1RAs）与心脏代谢保护：历史发展与未来挑战
Cardiovasc Diabetol. 2025 Mar 12;24(1):118. doi: 10.1186/s12933-025-02647-2.
本文引用的文献
1
Proteomic changes upon treatment with semaglutide in individuals with obesity.司美格鲁肽治疗肥胖个体后的蛋白质组学变化。
Nat Med. 2025 Jan;31(1):267-277. doi: 10.1038/s41591-024-03355-2. Epub 2025 Jan 3.
2
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.数据驱动的聚类分析识别出代谢功能障碍相关脂肪性肝病的不同类型。
Nat Med. 2024 Dec;30(12):3624-3633. doi: 10.1038/s41591-024-03283-1. Epub 2024 Dec 9.
3
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.胰高血糖素样肽-1受体激动剂对肾脏和心血管疾病结局的影响：一项随机对照试验的荟萃分析。
Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25.
4
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.替尔泊肽对射血分数保留的肥胖心力衰竭患者临床病程的影响。
Circulation. 2025 Mar 11;151(10):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. Epub 2024 Nov 18.
5
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.替尔泊肽用于射血分数保留的心力衰竭合并肥胖症
N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16.
6
Evaluating the benefits of the early use of GLP-1 receptor agonists.评估早期使用胰高血糖素样肽-1（GLP-1）受体激动剂的益处。
Lancet. 2025 Jan 18;405(10474):181-183. doi: 10.1016/S0140-6736(24)02255-4. Epub 2024 Nov 12.
7
The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity.GLP-1 类药物的发现和开发彻底改变了肥胖症的治疗方法。
Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2415550121. doi: 10.1073/pnas.2415550121. Epub 2024 Sep 19.
8
Discovery of GLP-1-Based Drugs for the Treatment of Obesity.用于治疗肥胖症的基于胰高血糖素样肽-1的药物的发现。
N Engl J Med. 2025 Feb 6;392(6):612-615. doi: 10.1056/NEJMcibr2409089. Epub 2024 Sep 19.
9
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.利拉鲁肽用于6至<12岁肥胖儿童——一项随机试验
N Engl J Med. 2025 Feb 6;392(6):555-565. doi: 10.1056/NEJMoa2407379. Epub 2024 Sep 10.
10
The benefits of GLP-1 drugs beyond obesity.胰高血糖素样肽-1（GLP-1）药物在治疗肥胖症之外的益处。
Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.
Zotero 插件